Pfizer vaccine is after all 95% efficiency



[ad_1]

There have been several news on vaccines since last week. Pfizer was the first to announce this, having revealed that its vaccine was “90% effective”. Modern pharmaceuticals followed and today the revelation that the Chinese Coronavac vaccine is “safe”.

Pfizer also revealed today that its vaccine is 95% effective after all.

COVID-19: Pfizer vaccine is after all 95% efficiency

As we've already mentioned here, the results of three potential vaccines to fight COVID-19 were revealed within two weeks. The first was the Pfizer vaccine (90%), followed by the modern drug (94.5%) and Coronavac, which is known to be "safe".

The Pfizer vaccine is 95% effective from 28 days

However, the first full clinical trial results show greater efficacy than previously announced by the manufacturers, reveals the journal Publico.

The presented vaccine is 95% effective starting 28 days after the first dose, with no serious side effects, according to the first comprehensive clinical trial results. The disclosure was made via a statement that is available on the Pfizer website - see here.

COVID-19: Pfizer vaccine is after all 95% efficiency

In this phase 3 44,000 volunteers participated. The vaccine was given in two doses three weeks apart.

The results show that of the 170 recorded cases of infection, 162 occurred in the group that received the placebo and the rest in the group that received the vaccine. Ten severe cases of COVID-19 have been counted, nine of them in people who received the placebo.

The percentage update is due to the fact that the company has announced preliminary results. Pfizer had said testing would continue until at least 164 cases of COVID-19 were detected. With the new data, the percentage with respect to efficiency has also been updated, which rises to 95%.

The company is now preparing to apply for emergency clearance in the United States. As for the side effects, the results show that some patients have been fatigued for a time and some have had headaches.

Read also ...



[ad_2]
Source link